9 results on '"Plug, Iris"'
Search Results
2. Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain
- Author
-
MS Radiologie, Circulatory Health, Ebbink, Berendine J, Poelman, Esther, Aarsen, Femke K, Plug, Iris, Régal, Luc, Muentjes, Carsten, van der Beek, Nadine A M E, Lequin, Maarten H, van der Ploeg, Ans T, van den Hout, Johanna M P, MS Radiologie, Circulatory Health, Ebbink, Berendine J, Poelman, Esther, Aarsen, Femke K, Plug, Iris, Régal, Luc, Muentjes, Carsten, van der Beek, Nadine A M E, Lequin, Maarten H, van der Ploeg, Ans T, and van den Hout, Johanna M P
- Published
- 2018
3. Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain.
- Author
-
Ebbink, Berendine J., Poelman, Esther, Aarsen, Femke K., Plug, Iris, Régal, Luc, Muentjes, Carsten, van der Beek, Nadine A. M. E., Lequin, Maarten H., van der Ploeg, Ans T., and van den Hout, Johanna M. P.
- Subjects
GLYCOGEN storage disease ,MAGNETIC resonance imaging ,NEUROPSYCHOLOGICAL tests ,COGNITIVE development ,GENETIC mutation ,AGE distribution ,BRAIN ,DRUG therapy ,COGNITION disorders ,COMPARATIVE studies ,DIGITAL image processing ,INTELLECT ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,VENTILATION ,EVALUATION research ,DISEASE progression ,INBORN errors of carbohydrate metabolism ,DISEASE complications - Abstract
Copyright of Developmental Medicine & Child Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2018
- Full Text
- View/download PDF
4. Genotype-phenotype relationship in mucopolysaccharidosis II: predictive power of IDS variants for the neuronopathic phenotype.
- Author
-
Vollebregt, Audrey A M, Hoogeveen‐Westerveld, Marianne, Kroos, Marian A, Oussoren, Esmee, Plug, Iris, Ruijter, George J, van der Ploeg, Ans T, and Pijnappel, W W M Pim
- Subjects
MUCOPOLYSACCHARIDOSIS II ,GENOTYPES ,PHENOTYPES ,SULFATASES ,INTELLECTUAL disabilities ,GLYCOSAMINOGLYCANS ,EPILEPSY & psychology ,EPILEPSY ,GENETICS ,GENETIC techniques ,GLYCOPROTEINS ,IMMUNOBLOTTING ,INTELLECT ,LONGITUDINAL method ,MASS spectrometry ,EDUCATIONAL attainment ,PSYCHOLOGY - Abstract
Copyright of Developmental Medicine & Child Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2017
- Full Text
- View/download PDF
5. Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up.
- Author
-
Güngör, Deniz, Kruijshaar, Michelle, Plug, Iris, Rizopoulos, Dimitris, Kanters, Tim, Wens, Stephan, Reuser, Arnold, Doorn, Pieter, and Ploeg, Ans
- Abstract
Background: Pompe disease is an inheritable metabolic disorder for which enzyme replacement therapy (ERT) has been available since 2006. Effects of ERT have been shown on distance walked, pulmonary function and survival. We investigated whether it also improves quality of life and participation in daily life in adult patients with the disease. Methods: In an international survey, we assessed quality of life (Short Form 36, SF-36) and participation (Rotterdam Handicap Scale, RHS) annually between 2002 and 2012. Repeated measurements mixed effects models were used to describe the data over time. Results: Responses were available for 174 adult patients. In the periods before and after start of ERT, the median follow-up times were 4 years each (range 0.5-8). The SF-36 Physical Component Summary measure (PCS) deteriorated before ERT (-0.73 score points per year (sp/y); CI 95 % -1.07 to -0.39), while it improved in the first 2 years of ERT (1.49 sp/y; CI 0.76 to 2.21), and remained stable thereafter. The Mental Component Summary measure (MCS) remained stable before and during ERT. After declining beforehand (-0.49 sp/year; CI -0.64 to-0.34), the RHS stabilized under ERT. Conclusion: In adult patients with Pompe disease, ERT positively affects quality of life and participation in daily life. Our results reinforce previous findings regarding the effect of ERT on muscle strength, pulmonary function and survival. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
6. Long-term cognitive follow-up in children treated for Maroteaux-Lamy syndrome.
- Author
-
Ebbink, Berendine, Brands, Marion, Hout, Johanna, Lequin, Maarten, Braak, Robert, Weitgraven, Rianne, Plug, Iris, Aarsen, Femke, and Ploeg, Ans
- Abstract
Background: It remains unclear to what extent the brain is affected by Maroteaux-Lamy syndrome (MPS VI), a progressive lysosomal storage disorder. While enzyme replacement therapy (ERT) elicits positive effects, the drug cannot cross the blood-brain barrier. We therefore studied cognitive development and brain abnormalities in the Dutch MPS VI patient population treated with ERT. Methods: In a series of 11 children with MPS VI (age 2 to 20 years), we assessed cognitive functioning and brain magnetic resonance imaging prospectively at the start of ERT and at regular times thereafter up to 4.8 years. We also assessed the children's clinical characteristics, their siblings' cognitive development, and their parents' educational levels. Results: The patients' intelligence scores ranged from normal to mentally delayed (range test scores 52-131). In 90 %, their scores remained fairly stable during follow-up, generally lying in the same range as their siblings' test scores (median for patients = 104, median for siblings = 88) and comparing well with the parental educational levels. Native-speaking patients had higher intelligence test scores than non-native-speaking patients. Two patients, both with high baseline glycosaminoglycan levels in their urine and severe mutations in the arylsulfatase B gene, scored clearly lower than expected. Patients with pY210C performed best. Brain abnormalities were aspecific, occurring more in patients with severe symptoms. Conclusion: Our study shows that cognitive development in MPS VI patients is determined not only by familial and social-background factors, but, in patients with a severe form of the disease, also by the disease itself. Therefore in patients with severe disease presentation cognition should be monitored carefully. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
7. Pain: a prevalent feature in patients with mucopolysaccharidosis. Results of a cross-sectional national survey.
- Author
-
Brands, Marion, Güngör, Deniz, Hout, Johanna, Karstens, Francois, Oussoren, Esmee, Plug, Iris, Boelens, Jaap, Hasselt, Peter, Hollak, Carla, Mulder, Margot, Gozalbo, Estela, Smeitink, Jan, Smit, G., Wijburg, Frits, Meutgeert, Hanka, and Ploeg, Ans
- Abstract
Background: While clinical observations suggest that many patients with mucopolysaccharidosis (MPS) experience chronic pain, few studies have assessed its extent and impact. We therefore investigated its prevalence in patients with all types of MPS in the Netherlands. We also examined the association between pain and health related quality of life (HRQoL) and other clinical variables. Methods: We conducted a nationwide MPS survey that used questionnaires on MPS and disease-related symptoms (MPS-specific questionnaire), developmental level (Vineland Screener 0-6 years), quality of life (PedsQl and SF-36), and disability (Childhood Health Assessment Questionnaire). Depending on their age and developmental level, patients or their parents were asked to assess pain by keeping a pain diary for five consecutive days: either the Non-communicating Children's Pain Checklist - Revised (3-18 years intellectually disabled and children <8 years), the VAS-score (> 18 years), or the Faces Pain Scale - Revised (8-18 years). Results: Eighty-nine MPS patients were invited, 55 of whom agreed to participate (response rate 62 %; median age 10.9 years, range 2.9-47.2 years). They covered a wide spectrum in all age groups, ranging from no pain to severe pain. Forty percent scored above the cut-off value for pain. Most reported pain sites were the back and hips. While the MPS III group experienced the highest frequency of pain (52.9 %), 50 % of patients with an intellectual disability seemed to experience pain, versus 30 % of patients with a normal intelligence. MPS patients scored much lower (i.e., more pain) than a random sample of the Dutch population on the bodily pain domain of the SF-36 scale and the PedsQl. Conclusion: With or without intellectual disabilities, many MPS patients experience pain. We recommend that standardized pain assessments are included in the regular follow-up program of patients with MPS. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
8. Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease.
- Author
-
Gelder, Carin, Hoogeveen-Westerveld, Marianne, Kroos, Marian, Plug, Iris, Ploeg, Ans, and Reuser, Arnold
- Abstract
Background: Enzyme-replacement therapy (ERT) in Pompe disease-an inherited metabolic disorder caused by acid α-glucosidase deficiency and characterized in infants by generalized muscle weakness and cardiomyopathy-can be complicated by immune responses. Infants that do not produce any endogenous acid α-glucosidase, so-called CRIM-negative patients, reportedly develop a strong response. We report the clinical outcome of our Dutch infants in relation to their CRIM status and immune response. Methods: Eleven patients were genotyped and their CRIM status was determined. Antibody formation and clinical outcome were assessed for a minimum of 4 years. Results: ERT was commenced between 0.1 and 8.3 months of age, and patients were treated from 0.3 to 13.7 years. All patients developed antibodies. Those with a high antibody titer (above 1:31,250) had a poor response. The antibody titers varied substantially between patients and did not strictly correlate with the patients' CRIM status. Patients who started ERT beyond 2 months of age tended to develop higher titers than those who started earlier. All three CRIM-negative patients in our study succumbed by the age of 4 years seemingly unrelated to the height of their antibody titer. Conclusion: Antibody formation is a common response to ERT in classic infantile Pompe disease and counteracts the effect of treatment. The counteracting effect seems determined by the antibody:enzyme molecular stoichiometry. The immune response may be minimized by early start of ERT and by immune modulation, as proposed by colleagues. The CRIM-negative status itself seems associated with poor outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
9. The timing of introduction of pharmaceutical innovations in seven European countries.
- Author
-
Westerling, Ragnar, Westin, Marcus, McKee, Martin, Hoffmann, Rasmus, Plug, Iris, Rey, Grégoire, Jougla, Eric, Lang, Katrin, Pärna, Kersti, Alfonso, José L., and Mackenbach, Johan P.
- Subjects
BREAST tumor treatment ,ULCER treatment ,PEPTIC ulcer ,TAMOXIFEN ,TESTIS tumors ,MEDICAL care ,CIMETIDINE ,CISPLATIN ,DIFFUSION of innovations ,CLINICAL drug trials ,MEDICAL practice ,PATIENTS ,DATA analysis ,TUMOR treatment - Abstract
Rationale, aims and objectives Differences in the performance of medical care may be due to variation in the introduction and diffusion of medical innovations. The objective of this paper is to compare seven European countries ( United Kingdom, the Netherlands, West Germany, France, Spain, Estonia and Sweden) with regard to the year of introduction of six specific pharmaceutical innovations (antiretroviral drugs, cimetidine, tamoxifen, cisplatin, oxalaplatin and cyclosporin) that may have had important population health impacts. Methods We collected information on introduction and further diffusion of drugs using searches in the national and international literature, and questionnaires to national informants. We combined various sources of information, both official years of registration and other indicators of introduction (clinical trials, guidelines, evaluation reports, sales statistics). Results and conclusions The total length of the period between first and last introduction varied between 8 years for antiretroviral drugs and 22 years for cisplatin. Introduction in Estonia was generally delayed until the 1990s. The average time lags were smallest in France (2.2 years), United Kingdom (2.8 years) and the Netherlands (3.5 years). Similar rank orders were seen for year of registration suggesting that introduction lags are not only explained by differences in the process of registration. We discuss possible reasons for these between-country differences and implications for the evaluation of medical care. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.